Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 19/20 | 0.60 |
| ▸ | TACR3 | P29371 | 12/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876430 | 0.91 | TACR1 (0.72) | TACR1TACR3CYP3A4 | |
| SCHEMBL1872510 | 0.90 | TACR1 (0.64) | TACR1TACR3CYP3A4 | |
| SCHEMBL1872508 | 0.90 | TACR1 (0.64) | TACR1TACR3CYP3A4 | |
| SCHEMBL1874144 | 0.90 | TACR1 (0.61) | TACR1TACR3CYP3A4 | |
| SCHEMBL1874069 | 0.89 | TACR1 (0.65) | TACR1TACR3CYP3A4 | |
| SCHEMBL1870165 | 0.88 | TACR1 (0.60) | TACR1TACR3CYP3A4 | |
| SCHEMBL1873453 | 0.88 | TACR1 (0.60) | TACR1TACR3CYP3A4 | |
| SCHEMBL1868483 | 0.88 | TACR1 (0.61) | TACR1TACR3CYP3A4 | |
| SCHEMBL1874399 | 0.87 | TACR1 (0.63) | TACR1TACR3CYP3A4 | |
| SCHEMBL1873164 | 0.87 | TACR1 (0.62) | TACR1TACR3CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | F. HOFMANN-LA ROCHE AG (CH) | 2005-04-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090533-A1 | Dual NK1/NK3 receptor antagonists | TACR2, TAC3, TACR1 | TACR1 3/4885TACR3 4/4885CYP3A4 3029/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.